A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer

14Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Both bevacizumab and anti-epithelial growth factor receptor (EGFR) agents (e.g. cetuximab and panitumumab) are sequentially used for metastatic colorectal cancer (mCRC). Their coadministration as a first-line treatment does not improve outcome, indicating that there are negative interactions between these agents. A long-term pharmacokinetics study demonstrated serum persistence of bevacizumab following termination of bevacizumab 6 months after the last administration. This prompted us to investigate the impact of short intervals between bevacizumab and anti-EGFR antibody on the efficacy of subsequent anti-EGFR therapy. Methods: We retrospectively reviewed consecutive patients with KRAS exon 2 wild-type mCRC who underwent anti-EGFR therapy after the failure of fluoropyrimidines, oxaliplatin and irinotecan. We divided patients into two groups (Group A: the interval between bevacizumab and anti-EGFR agent< 6 months; Group B: the interval >6 months). Results: Of the 114 included patients (median age, 63 years), 78 (68%) were male. Most patients (88%) were treated with cetuximab plus irinotecan. Groups A and B consisted of 74 and 40 patients, respectively. There were no significant differences in patient characteristics. Group B patients had significantly longer progression-free survival (4.2 vs. 6.6 months; HR, 0.65; 95% CI, 0.43-0.98; P = 0.038) and longer overall survival (11.6 vs. 14.3 months; HR, 0.63; 95% CI, 0.41-0.98, P = 0.039). The response rate was 24.3% in Group A and 47.5% in Group B (P = 0.012). Conclusion: A short interval between bevacizumab and anti-EGFR antibody treatment may interfere with the efficacy of subsequent anti-EGFR therapy.

References Powered by Scopus

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

9686Citations
N/AReaders
Get full text

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer

4794Citations
N/AReaders
Get full text

K-ras mutations and benefit from cetuximab in advanced colorectal cancer

3302Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

137Citations
N/AReaders
Get full text

Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

103Citations
N/AReaders
Get full text

Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies

41Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Taniguchi, H., Komori, A., Narita, Y., Kadowaki, S., Ura, T., Andoh, M., … Muro, K. (2016). A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer. Japanese Journal of Clinical Oncology, 46(3), 228–233. https://doi.org/10.1093/jjco/hyv193

Readers over time

‘16‘17‘18‘19‘20‘21‘22‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 6

40%

Researcher 4

27%

Professor / Associate Prof. 3

20%

Lecturer / Post doc 2

13%

Readers' Discipline

Tooltip

Medicine and Dentistry 19

73%

Pharmacology, Toxicology and Pharmaceut... 3

12%

Agricultural and Biological Sciences 2

8%

Immunology and Microbiology 2

8%

Save time finding and organizing research with Mendeley

Sign up for free
0